Effect of Honey For CIN II
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorZuyderland Medisch Centrum
About this trial
The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.
Eligibility criteria
Qualifiers
Women 18-40 years
Primary CIN II confirmed histologically in the biopsy on colposcopic examination
Sufficient mastery of the Dutch language
Disqualifiers
Simultaneous abnormality in columnar epithelial cells (AIS).
Hr-HPV negative cytology
Immunosuppressant use/Autoimmune disease (HIV, CVID)
History of cervical carcinoma or previous treatment for CIN (LLETZ or imiquimod)
Trial design
Treatments tested in this trial
- Medical grade honey formulation (MGH) (L-Mesitran®)
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov